CorMedix vs Phathom Pharmaceuticals
CRMD and PHAT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRMD and PHAT compare
Phathom Pharmaceuticals is the larger company, worth 1.4 times as much as CorMedix ($493M against $363M).
CorMedix grew revenue faster over the last twelve months (92.5% versus 86.8% for Phathom Pharmaceuticals).
CorMedix keeps more of each dollar of sales as profit, with a net margin of 15.5% compared with −30.2% at Phathom Pharmaceuticals.
CorMedix scores higher on the StockData Score (15 against 4 for Phathom Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRMD | PHAT |
|---|---|---|
| Size and price | ||
| Market cap | $363M | $493M |
| Share price | $4.66 | $6.06 |
| Change, 1 year | −59.2% | −58.5% |
| Change, 5 years | −9.2% | −69.8% |
| Beta (5Y) | 1.37 | 1.63 |
| Employees | 191 | 371 |
| StockData Score | ||
| Total score | 15 (better) | 4 |
| Valuation score | 3 (better) | 1 |
| Growth score | 3 (better) | 1 |
| Performance score | 4 (better) | 1 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.9× (better) | 1.8× |
| P/B | 0.8× | – |
| EV/EBITDA | 0.1× | – |
| P/FCF | 1.2× | – |
| FCF yield | 84.8% (better) | −4.3% |
| Fair value | $34.62 | – |
| Margin of safety | 86.5% | – |
| Growth | ||
| Revenue growth (TTM) | 92.5% (better) | 86.8% |
| Revenue growth, 5Y average | 320% | – |
| Net income growth (TTM) | −60.7% | – |
| Profitability | ||
| Gross margin | 77.5% | 80.7% (better) |
| Operating margin | 38.6% (better) | −9.3% |
| Net margin | 15.5% (better) | −30.2% |
| FCF margin | 74.6% (better) | −7.7% |
| Return on equity | 15.3% | – |
| Return on invested capital | 37.4% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −0.4× |
| Current ratio | 2.43 (better) | 1.76 |
| Altman Z-score | 1.69 (better) | −4.83 |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | −3.1% | – |
| Shareholder yield | −3.1% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 56.5% | 88.7% |
| Held by insiders | 3.2% | 12.2% |
| Insider net buying, 12 months | −$2.0M | $0 (better) |
| Short interest, % of float | 18.8% | 12.9% |
Go deeper
- CRMD stock overview
- CRMD income statement
- CRMD valuation and score
- PHAT stock overview
- PHAT income statement
- PHAT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.